Don Luo

2.6k total citations
23 papers, 817 citations indexed

About

Don Luo is a scholar working on Surgery, Hepatology and Economics and Econometrics. According to data from OpenAlex, Don Luo has authored 23 papers receiving a total of 817 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 7 papers in Hepatology and 6 papers in Economics and Econometrics. Recurrent topics in Don Luo's work include Lipoproteins and Cardiovascular Health (7 papers), Hepatitis C virus research (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Don Luo is often cited by papers focused on Lipoproteins and Cardiovascular Health (7 papers), Hepatitis C virus research (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Don Luo collaborates with scholars based in United States, Sweden and China. Don Luo's co-authors include Michael Szarek, Susan D. Ross, Connie B. Newman, E Gibson, Janet E. Connelly, Moira Smith, Isabel Elaine Allen, Juan Cosín‐Aguilar, Nevres Koylan and Karin Schenck‐Gustafsson and has published in prestigious journals such as Circulation, Gastroenterology and Diabetes Care.

In The Last Decade

Don Luo

22 papers receiving 768 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Don Luo United States 11 500 266 184 172 132 23 817
Yea Huei Kao Yang Taiwan 9 304 0.6× 120 0.5× 153 0.8× 219 1.3× 109 0.8× 12 856
Ali Raza United States 10 553 1.1× 255 1.0× 163 0.9× 78 0.5× 57 0.4× 30 812
Sören Madsen Denmark 12 719 1.4× 158 0.6× 200 1.1× 139 0.8× 70 0.5× 17 1.4k
Bruce A. Warden United States 16 417 0.8× 147 0.6× 142 0.8× 504 2.9× 96 0.7× 35 1.0k
Annemarie Armani United States 8 305 0.6× 72 0.3× 215 1.2× 155 0.9× 90 0.7× 14 585
Mohamed A. Omar Canada 13 464 0.9× 135 0.5× 113 0.6× 130 0.8× 75 0.6× 31 968
Benjamin Neely United States 9 512 1.0× 257 1.0× 198 1.1× 373 2.2× 65 0.5× 20 1.0k
Mike J. Warwick United Kingdom 12 485 1.0× 213 0.8× 105 0.6× 81 0.5× 81 0.6× 14 873
David Neff United States 17 938 1.9× 299 1.1× 394 2.1× 269 1.6× 93 0.7× 39 1.4k
Roberto Scicali Italy 22 350 0.7× 40 0.2× 474 2.6× 264 1.5× 339 2.6× 51 1.2k

Countries citing papers authored by Don Luo

Since Specialization
Citations

This map shows the geographic impact of Don Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don Luo more than expected).

Fields of papers citing papers by Don Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don Luo. The network helps show where Don Luo may publish in the future.

Co-authorship network of co-authors of Don Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Don Luo. A scholar is included among the top collaborators of Don Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don Luo. Don Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ehlers, Justis P., Gagan Kalra, Jamie Reese, et al.. (2024). Correlation Between Blue Fundus Autofluorescence and SD-OCT Measurements of Geographic Atrophy in Dry Age-Related Macular Degeneration. American Journal of Ophthalmology. 266. 92–101. 3 indexed citations
2.
Luo, Don. (2015). Research Progress in the Biological Basis of Legume Pod Dehiscence. Acta Agrestia Sinica. 1 indexed citations
3.
Luo, Don. (2014). Clinical Significance of PEBP4,Cripto-1 Expressions in Esophageal Carcinoma. 1 indexed citations
4.
Pol, Stanislas, Jeroen Aerssens, Stefan Zeuzem, et al.. (2013). Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. Journal of Hepatology. 58(5). 883–889. 41 indexed citations
5.
Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2012). Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. Journal of Hepatology. 58(3). 488–494. 10 indexed citations
6.
Adda, Nathalie, Doug J. Bartels, Linda Gritz, et al.. (2012). Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 11(2). 193–195. 8 indexed citations
7.
8.
Lawitz, Eric, Graham R. Foster, Stefan Zeuzem, et al.. (2011). Subanalyses of the Telaprevir Lead-in ARM in the Realize Study: Response at Week 4 is Not a Substitute for Prior Null Response Categorization. Gastroenterology. 140(5). S–911. 6 indexed citations
9.
Muir, Andrew J., Sandra Gavart, G. Nuyts, et al.. (2011). Impact of Telaprevir-Based Treatment Regimens on Fatigue in Genotype 1 HCV Treatment-NaïVE Patients: Results From Advance and Illuminate Studies. Gastroenterology. 140(5). S–944. 1 indexed citations
10.
Younossi, Zobair M., Jeroen Aerssens, Stanislas Pol, et al.. (2011). Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study. Gastroenterology. 140(5). S–907. 16 indexed citations
11.
Deedwania, Prakash, Peter H. Stone, C. Noel Bairey Merz, et al.. (2007). Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Circulation. 115(6). 700–707. 171 indexed citations
12.
Luo, Don. (2007). Engineering project management. Shanxi Architecture. 8 indexed citations
13.
Karalis, Dean G., et al.. (2007). Effects of Increasing Doses of Atorvastatin on the Atherogenic Lipid Subclasses Commonly Associated With Hypertriglyceridemia. The American Journal of Cardiology. 100(3). 445–449. 25 indexed citations
14.
Olsson, Anders, Gregory G. Schwartz, Michael Szarek, Don Luo, & M. J. Jamieson. (2007). Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study). The American Journal of Cardiology. 99(5). 632–635. 49 indexed citations
15.
Hey‐Hadavi, Judith, et al.. (2006). Tolerability of atorvastatin in a population aged ≥65 years: A retrospective pooled analysis of results from fifty randomized clinical trials. ˜The œAmerican journal of geriatric pharmacotherapy. 4(2). 112–122. 18 indexed citations
16.
Neil, H. A. W., David A. DeMicco, Don Luo, et al.. (2006). Analysis of Efficacy and Safety in Patients Aged 65–75 Years at Randomization. Diabetes Care. 29(11). 2378–2384. 84 indexed citations
17.
Newman, Connie B., et al.. (2005). Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. The American Journal of Cardiology. 97(1). 61–67. 123 indexed citations
18.
Tougas, Gervais, et al.. (2003). Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology. 124(4). A54–A54. 52 indexed citations
19.
Stason, William B., Christopher H. Schmid, Donna Niedzwiecki, et al.. (1999). Safety of Nifedipine in Angina Pectoris. Hypertension. 33(1). 24–31. 28 indexed citations
20.
Ross, Susan D., et al.. (1999). Clinical outcomes in statin treatment trials: a meta-analysis.. PubMed. 159(15). 1793–802. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yea Huei Kao Yang Breakdown of academic impact, for papers by Ali Raza Breakdown of academic impact, for papers by Sören Madsen Breakdown of academic impact, for papers by Bruce A. Warden Breakdown of academic impact, for papers by Annemarie Armani Breakdown of academic impact, for papers by Mohamed A. Omar Breakdown of academic impact, for papers by Benjamin Neely Breakdown of academic impact, for papers by Mike J. Warwick Breakdown of academic impact, for papers by David Neff Breakdown of academic impact, for papers by Roberto Scicali
Rankless by CCL
2026